Condition 1: Burn. Condition 2: Burn. Condition 3: Burn. Condition 4: Burn. Condition 5: Burn. Condition 6: Burn. Condition 7: Burn. Condition 8: Burn. Burn and corrosion of head, face, and neck Burn and corrosion of trunk Burn and corrosion of shoulder and upper limb, except wrist and hand Burn and corrosion of wrist and hand Burn and corrosion of lower limb, except ankle and foot Burn and corrosion of ankle and foot Burn and corrosion confined to eye and adnexa Burn and corrosion of re
Conditions
Interventions
Intervention 1: Intervention group: 150 international units of recombinant human EPO (rhEPO) (NeoRecormon Multidose 50,000 IU, Roche, Grenzach-Wylen, Germany) per kilogram of body weight administered
Sponsors
Sanandaj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 2nd and 3rd degree burns Men and women, ages 18 to 75 Safe pregnancy prevention
Exclusion criteria
Exclusion criteria: Admission later than 24 hours after injury. Hematologic disorders (anemia, lymphoma, leukemia, congenital coagulation disorders). Pregnancy or breastfeeding Estimated survival of less than one week (Abstract Burn Severity Index (ABSI) > 12) in patients older than 40 years of age. Body weight less than 50 kg or more than 110 kg in patients over 40 years of age with a burn level of less than 60%. In patients under 40 years of age, there will be no limit on the maximum body surface area burned and no limit on the ABSI score. The upper lateral thigh of both legs has suffered thermal damage. Treatment with any product studied in the past 12 months prior to study entry Immunosuppressive therapy, cancer-related chemotherapy, or radiation therapy in the past 12 months. History of hypersensitivity to same products The possibility of needing treatment during the study period with medications that are not permitted according to the clinical study protocol Cardiovascular Disease (myocardial infarction, Coronary Heart Disease (CHD), refractory hypertension, thromboembolic disease, thromboembolic events shortly before admission), hepatic (Child's liver disease B or C), endocrine (morbid obesity (BMI > 40)) or systemic disease (cancer) (malignancy). Epileptic diseases Phenylketonuria HIV disease, AIDS Lack of consent from the patient or the patient's guardian to participate or continue in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospital stay. Timepoint: all hospital stay. Method of measurement: case file.;Mortalite. Timepoint: all hospital stay. Method of measurement: case file.;Urin out put. Timepoint: 48 hour. Method of measurement: urin bag volume.;Ventilator dependance. Timepoint: all hospital stay. Method of measurement: case file. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarhang Safarnejad
Sanandaj University of Medical Sciences
Outcome results
None listed